Clinical trials: Stage 1 Hypertension
Hypertension
Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
To test bioequivalence of Doxazosin 4 Mg Orally-disintegrating Tablet with Or Without Water to Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition
- Trial name
- NCT01389609
- Testing
- Doxazosin 4 mg Japanese marketed IR tablet, Doxazosin 4 mg ODT with water, Doxazosin 4 mg ODT without water
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Breast Cancer, Cardiovascular Complications
Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure.
- Conditions
- Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer
- Trial name
- NCT01096381
- Testing
- laboratory biomarker analysis, questionnaire administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Prehypertension, Hypertension, Stage I
Effect of Ginseol Kg1 on Blood Pressure Lowering
In this study, we investigate the effects of Ginseol Kg1 (Korea red ginseng extract) on blood pressure in prehypertensive or stage I hypertensive patients.
- Trial name
- NCT01483430
- Testing
- Ginseol Kg1 (low dose), Ginseol Kg1(high dose)
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Seoul National University Hospital
Pulmonary Arterial Hypertension
Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on single and multiple ascending doses of KAR5585 in healthy adults.
- Trial name
- NCT02746237
- Testing
- KAR5585 Capsules
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Karos Pharmaceuticals
Ocular Hypertension
Study of ST266 Given by Intranasal Delivery in Glaucoma Suspect Subjects
The primary objective of this trial is to assess the safety of ST266 given by non-invasive intranasal trans-cribriform delivery to glaucoma suspect subjects with ocular hypertension, optic nerve cupping, or family history of…
- Trial name
- NCT03901781
- Testing
- ST266 via Intranasal Delivery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Noveome Biotherapeutics, formerly Stemnion
Pulmonary Arterial Hypertension
Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
A Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers
- Trial name
- NCT03464864
- Testing
- Treprostinil Inhalation Powder
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Hypertension
Drug-Drug Interaction Study Between HUC2-565-A and HUC2-565-B
The purpose of this study is to evaluate a pharmacokinetic drug interaction and safety.
- Trial name
- NCT06618079
- Testing
- HUC2-565-A, HUC2-565-A and HUC2-565-B, HUC2-565-B, HUC2-565-A and HUC2-565-B
- Where
- South Korea
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
PAH, Pulmonary Hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health…
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03626688
- Testing
- Ralinepag
- Where
- 209 sites in United States, Argentina and 31 more
- Volunteers
- 687 people
- Sponsor
- United Therapeutics
HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension
This is a Phase 2a, open-label, multiple-dose study to assess the safety, tolerability, and efficacy of JK07 in participants 18 to 85 years of age with diagnosed HF and cpcPH.
- Conditions
- HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
- Trial name
- RENEU-PH (NCT07221513)
- Testing
- JK07
- Where
- United States
- Sponsor
- Salubris Biotherapeutics Inc
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Elevated Blood Pressure
'Low-salt' Bread as a Means of Reducing Dietary Salt and Lowering Blood Pressure
In the context of public health, reformulation of bread in terms of salt content remains an important measure to help achieve a reduction in salt intake in the population.
- Trial name
- Saltbreads (NCT04003597)
- Testing
- Usual-salt diet, Reduced-salt diet
- Where
- Ireland
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- University College Cork
Hypertension, Health Services Accessibility
A Combination Triple Pill Implementation Strategy for Blood Pressure cONtrol
This study includes a survey of primary healthcare facilities in Nigeria and Sri Lanka. It will aim to assess the availability and readiness of hypertension care in primary healthcare facilities, and feasibility to conduct a…
- Trial name
- ACTION (NCT07784647)
- Where
- 2 sites in Nigeria, Sri Lanka
- Volunteers
- 1,444 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hypertension
Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension
The Wave VI study is a, multicenter, prospective, double-blind, randomized, sham controlled feasibility study of the safety of renal denervation in patients with stage I and II hypertension who have an average office systolic…
- Trial name
- NCT02480517
- Testing
- Ultrasound
- Volunteers
- 60 people
- Sponsor
- Kona Medical Inc.
Ocular Hypertension, Primary Open Angle Glaucoma
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution
The purpose of this Phase 1b study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AKB-9778 ophthalmic solution (eye drops) administered for 7 days in adults.
- Trial name
- NCT04284514
- Testing
- AKB-9778 Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Aerpio Therapeutics
Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)
The goal of this clinical trial is to evaluate the safety and tolerability of a single dose of ER-100 in adults with optic nerve conditions, specifically Open Angle Glaucoma (OAG) and Non-Arteritic Anterior Ischemic Optic…
- Trial name
- NCT07290244
- Testing
- ER-100 epigenetic therapy
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Life Biosciences Inc.
Metabolic Syndrome
Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome
Metabolic syndrome: aetiology, pathogenesis, diagnosis, clinical management and prognosis
- Trial name
- DRWMNTMS (NCT02503865)
- Testing
- Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin, "Analimentary detoxication"
- Where
- Kazakhstan
- Volunteers
- 351 people, healthy volunteers welcome
- Sponsor
- Nazarbayev University
Miscellaneous Disorders in the Fetus or Newborn
The Safety and Adverse Reaction Study of Neonatal to Inhaled Carbon Monoxide
Based on the study about carbon monoxide in human inflammatory and other beneficial physiological function , now we'll be going to research its application in neonates .Phase 1 Study as a foundation for the further test is, the…
- Trial name
- CO (NCT01818843)
- Testing
- Inhaled Carbon Monoxide
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- CAN WANG
Elevated LDL-C and High Cholesterol
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene.
- Trial name
- STX-1150-01 (NCT07428473)
- Testing
- STX-1150
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Monash University
Glaucoma, Ocular Hypertension
A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
To evaluate the steady-state systemic plasma concentrations of latanoprost acid following administration of latanoprost 0.005% (1.5 ug) in pediatric and adult subjects with glaucoma or ocular hypertension.
- Trial name
- NCT00638742
- Testing
- latanoprost
- Where
- 13 sites in United States, Denmark and 4 more
- Volunteers
- 47 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension PAH
Study of Intravenous ZMA001 in Healthy Subjects
Background: A number of diseases can cause a type of lung injury called pulmonary arterial hypertension (PAH). Most people who develop PAH do not survive more than a few years. A new study drug (ZMA001) may help.
- Trial name
- NCT05967299
- Testing
- ZMA001 (BC-NKA-20008)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)